UBS Group downgraded shares of Fate Therapeutics (NASDAQ:FATE) from an outperform rating to a market perform rating in a research note released on Tuesday morning, The Fly reports.
Several other equities research analysts have also issued reports on FATE. HC Wainwright reissued a buy rating and set a $7.00 price target on shares of Fate Therapeutics in a research report on Friday, November 10th. ValuEngine lowered Fate Therapeutics from a hold rating to a sell rating in a research report on Friday, December 1st. Raymond James Financial reissued a buy rating on shares of Fate Therapeutics in a research report on Tuesday, December 12th. Piper Jaffray Companies initiated coverage on Fate Therapeutics in a research report on Monday, December 18th. They set an overweight rating and a $10.00 price target on the stock. Finally, Wedbush reissued an outperform rating and set a $7.00 price target on shares of Fate Therapeutics in a research report on Monday, December 18th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Fate Therapeutics presently has a consensus rating of Buy and an average price target of $13.00.
Shares of Fate Therapeutics (FATE) opened at $13.17 on Tuesday. The company has a current ratio of 9.29, a quick ratio of 7.21 and a debt-to-equity ratio of 0.19. Fate Therapeutics has a 52-week low of $2.52 and a 52-week high of $14.45.
Hedge funds and other institutional investors have recently modified their holdings of the business. New York State Common Retirement Fund acquired a new stake in Fate Therapeutics in the second quarter worth $131,000. Raymond James & Associates acquired a new stake in Fate Therapeutics in the fourth quarter worth $141,000. Hochman Cole Investment Advisors Inc. acquired a new stake in Fate Therapeutics in the third quarter worth $158,000. The Manufacturers Life Insurance Company increased its position in Fate Therapeutics by 61.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 33,337 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 12,686 shares during the period. Finally, Schwab Charles Investment Management Inc. bought a new position in shares of Fate Therapeutics in the second quarter worth $214,000. 68.75% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://sportsperspectives.com/2018/03/10/ubs-group-downgrades-fate-therapeutics-fate-to-market-perform.html.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.